Cancer Genetics Launches Genomic Tests for Follicular Lymphoma and Mantle Cell Lymphoma - Further Extends Unique Position in ...
May 05 2014 - 8:00AM
- The Mantle-Cell and Follicular Lymphoma Tests Were Validated In
Research Collaborations With Memorial Sloan Kettering and Have Been
Successfully Licensed Under Both CLIA and New York State
Regulations
- Tests Address Over One-Third of non-Hodgkin Lymphomas And Will
Be Made Available As Part of Comprehensive Testing Programs To
Provide Targeted Diagnostic And Prognostic Information
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an
emerging leader in DNA-based diagnostics, today announced it has
received CLIA and New York state approvals for clinical use of its
proprietary mature B-cell neoplasm array, or MatBA® for Follicular
Lymphoma (MatBA®-FL) and Mantle-Cell Lymphoma (MatBA®-MCL). Both
tests further extend the portfolio in hematologic cancers being
developed by CGI and both were developed and validated via a
research collaboration with Memorial Sloan-Kettering Cancer Center.
MatBA®-FL and MatBA®-MCL assist clinicians in the prognosis of
Follicular Lymphoma (FL) and Mantle-Cell Lymphoma (MCL). MatBA®-FL
identifies genomic aberrations that are associated with the high
frequency of transformation of FL into Diffuse Large B-Cell
Lymphoma (DLBCL) and shorter overall survival (OS). MatBA®-MCL
identifies genomic aberrations that are associated with high
frequency of either a leukemic involvement and/or shorter OS.
Understanding the potential outcome for the patient is critical in
making informed choices about treatment selection, clinical trial
involvement and patient management.
Lymphoma is the most common form of blood cancer and is divided
into two main categories: Hodgkin Lymphoma (HL) and non-Hodgkin
lymphoma (NHL). In 2014, it is estimated that there will be 70,800
new cases of non-Hodgkin lymphoma and an estimated 18,990 people
will die of this disease. FL and MCL are two of several subtypes of
NHL. FL, a B-cell lymphoma, is the most common indolent (slow
growing) form of NHL, accounting for approximately 25% to 30% of
all non-Hodgkin lymphomas. Often, people with FL have no obvious
symptoms of the disease at diagnosis. MCL is a rare B-cell cancer
that most often affects men over the age of 60. The disease may be
very aggressive, but it can also behave in a more indolent fashion
in some patients. MCL comprises about 5% of all NHL. MCL is usually
diagnosed as a late-stage disease that has typically spread to the
gastrointestinal tract and bone marrow.
"The accurate and early diagnosis and prognosis of lymphomas is
central to providing more targeted and personalized treatment,"
said Panna Sharma, Chief Executive Officer of Cancer Genetics. "Our
MatBA® microarrays are highly validated and accurate genomic-based
tests designed to precisely give a prognosis, allowing doctors to
more accurately select treatments options. These tests also allow
drug development companies the opportunity to recruit the proper
patients into their clinical trials, and monitor genomic changes
and response during a trial thereby increasing the likelihood of
clinical trial success."
CGI's MatBA® platform has been designed to detect chromosomal
gains and losses at over 80 specific genomic sites associated with
mature B-cell neoplasms. MatBA® is designed for use in a clinical
laboratory and is optimized for use on a range of specimen types
such as peripheral blood, bone marrow, cell suspension, and
formalin-fixed paraffin-embedded tissue specimens. MatBA® improves
each patient's prognosis by determining the patient's unique
genetic profile, allowing doctors to more accurately select
treatments to which the patient is most likely to respond. No time
is wasted with treatment that will not work which is vital for many
cancers requiring immediate therapy.
The MatBA®-FL and MatBA-MCL joins the Diffuse Large B-Cell
Lymphoma (DLBCL) CompleteSM program offered by CGI, which includes
a suite of esoteric tests used in the diagnosis, prognosis and
clinical management of DLBCL patients. CGI is a Center of
Excellence for Chronic Lymphocytic Leukemia (CLL) and DLBCL
management by servicing world-class and proprietary capabilities
for the diagnosis, prognosis and monitoring of these diseases.
For more information on the MatBA product line, please visit
http://www.cancergenetics.com/products/matba/
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
lab is focused entirely on maintaining clinical excellence and is
both CLIA certified and CAP accredited and has licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute. For further information, please see
www.cancergenetics.com.
Forward-Looking Statements: This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
pertaining to future financial and/or operating results, future
growth in research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. products and services,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to, statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or discontinuance of trials,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights and other risks discussed in the
Company's Form 10-K for the year ended December 31, 2013 and other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer
Genetics disclaims any obligation to update these forward-looking
statements.
CONTACT: Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979
Media Relations
RedChip Companies, Inc.
Paul Kuntz, 800-733-2447, ext. 105
paul@redchip.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024